Home / Stocks / Alembic Pharma Ltd
APLLTD

Alembic Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,049.6

Change

+5.25 (0.5%)

Open

₹1,044.35

Prev. Close

₹1,044.35

Day High

₹1,054.25

Day Low

₹1,038.5

Volume Analysis

Traded

333,407

Delivered

212,373

Delivery %

63.7%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Trading within 3% of its 52-week high (₹1075.0)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (25.4%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,072.15 ₹1,063.2 ₹1,056.4 ₹1,047.45 ₹1,040.65 ₹1,031.7 ₹1,024.9
Fibonacci ₹1,063.2 ₹1,057.18 ₹1,053.47 ₹1,047.45 ₹1,041.43 ₹1,037.72 ₹1,031.7
Camarilla ₹1,053.93 ₹1,052.49 ₹1,051.04 ₹1,047.45 ₹1,048.16 ₹1,046.71 ₹1,045.27

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+25.3%

1 Week

+0.22%

1 Month

+33.21%

3 Months

+27.73%

6 Months

+38.89%

1 Year

+16.69%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹482.98

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.21%

Net margin 9.91% × asset turnover 0.77x × equity multiplier 1.6x

Company Overview

Sector

Healthcare

Market Cap

₹20,652 Cr

P/E (TTM)

23.0

ROE

13.4%

Book Value

₹302.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Alembic Pharma Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Cash Flow (42/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1075.0). Strong 3-year EPS growth (25.4%).

TopFund Score — Fundamentals Quality

69/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

44

Valuation

54

Cash Flow

42

Corporate Governance

90

Momentum

95

Institutional Ownership

54

Business Quality

64

Risk & Volatility

60

Liquidity

96

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 35.7%
  • −Stock is trading at 3.47 times its book value
  • −The company has delivered a poor sales growth of 6.37% over past five years.
  • −Tax rate seems low
  • −Company has a low return on equity of 12.7% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Alembic gets USFDA final approval for Binimetinib 15mg/45mg, with 180-day exclusivity.

Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026.

Please find attached Newspaper Publication related to Unaudited Financial Results of the Company for the quarter ended 30th September, 2026.

Alembic received USFDA final approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC) on 4 Nov 2026.

Audio recording of post-results conference call held on 4 November 2026 hosted on company website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,595 1,631 1,517 1,562 1,648 1,693 1,770 1,711 1,910 1,876 1,848 2,150 2,603
Expenses + 1,387 1,364 1,257 1,325 1,409 1,433 1,498 1,430 1,594 1,585 1,620 1,818 2,042
Operating Profit 208 266 260 237 239 260 271 281 316 292 228 332 562
OPM % 13.0% 16.0% 17.0% 15.0% 15.0% 15.0% 15.0% 16.0% 17.0% 16.0% 12.0% 15.0% 22.0%
Other Income + 10 3 4 2 30 10 14 6 8 -27 2 15 15
Interest 16 15 11 13 19 22 25 24 24 23 23 28 38
Depreciation 68 69 69 69 71 70 69 74 76 80 89 98 101
Profit before tax 135 185 183 157 180 178 192 190 224 162 119 222 438
Tax % -1.0% 2.0% 3.0% 14.0% 15.0% 23.0% 18.0% 19.0% 18.0% 18.0% -70.0% 22.0% 24.0%
Net Profit + 137 180 178 135 153 138 157 154 184 132 202 172 334
EPS in Rs 7 9 9 7 8 7 8 8 9 7 10 9 17
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 8 8 8 5 3 4 17 10 16 11 4 26 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 2,056 3,166 3,105 3,131 3,935 4,606 5,393 5,306 5,653 6,229 6,672 7,345 8,477
Expenses + 1,653 2,159 2,490 2,488 3,061 3,383 3,913 4,432 4,970 5,296 5,664 6,224 7,064
Operating Profit 403 1,007 615 643 874 1,223 1,480 874 682 932 1,008 1,121 1,413
OPM % 20.0% 32.0% 20.0% 21.0% 22.0% 27.0% 27.0% 16.0% 12.0% 15.0% 15.0% 15.0% 17.0%
Other Income + 4 7 2 7 9 -39 87 56 -2 28 56 -14 6
Interest 4 5 5 3 18 27 16 18 50 56 79 94 112
Depreciation 44 72 83 105 115 157 183 287 275 273 279 319 367
Profit before tax 359 936 529 541 749 1,000 1,368 625 355 632 707 694 940
Tax % 21.0% 23.0% 23.0% 22.0% 21.0% 20.0% 19.0% 17.0% 4.0% 3.0% 18.0% 3.0% —
Net Profit + 283 720 403 413 583 801 1,146 521 342 616 582 671 840
EPS in Rs 15 38 21 22 31 44 58 27 17 31 30 34 43
Dividend Payout % 23.0% 9.0% 19.0% 18.0% 18.0% 23.0% 24.0% 38.0% 46.0% 35.0% 37.0% 35.0% —
Sales growth 10 54 -2 1 26 17 17 -2 7 10 7 10 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 847 1,560 1,865 2,182 2,681 3,182 5,028 5,198 4,331 4,779 5,152 5,636 5,905
Borrowings + 264 114 89 708 1,128 1,747 584 717 722 513 1,258 1,430 1,547
Other Liabilities + 493 718 698 1,013 931 1,022 1,058 1,167 1,090 1,114 1,325 1,658 2,039
Total Liabilities 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773 8,763 9,531
Fixed Assets + 547 708 799 993 1,158 1,552 1,788 1,798 2,398 2,547 2,524 3,081 3,293
CWIP 83 93 396 1,010 1,551 1,846 2,183 2,304 601 524 837 683 543
Investments 2 87 50 42 49 18 236 118 96 93 127 141 153
Other Assets + 1,009 1,541 1,444 1,896 2,019 2,573 2,502 2,902 3,087 3,281 4,285 4,858 5,542
Total Assets 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773 8,763 9,531
Equity Capital 38 38 38 38 38 38 39 39 39 39 39 39 39

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 172 948 329 312 812 449 1,463 552 724 803 88 783
Cash from Investing Activity + -256 -307 -486 -884 -756 -731 -840 -372 -448 -321 -568 -506
Cash from Financing Activity + 87 -224 -129 503 59 155 -597 -217 -262 -438 444 -164
Net Cash Flow 3 417 -286 -69 115 -127 26 -37 14 45 -37 113
Free Cash Flow -52 647 348 -495 49 -285 804 128 282 487 -466 290
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 60 114 73 70 112 56 115 77 115 88 16 79

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.61% → 69.87%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.36% 10.54% 10.61% 10.38% 10.17% 9.96% 9.91% 9.92% 9.84% 9.83% 10.0% 10.16%
Promoters 69.61% 69.61% 69.61% 69.61% 69.61% 69.67% 69.68% 69.74% 69.74% 69.74% 69.87% 69.87%
FII 4.52% 4.46% 4.32% 3.94% 4.17% 3.94% 3.96% 4.04% 4.23% 4.26% 4.17% 4.55%
DII 14.51% 15.39% 15.47% 16.05% 16.05% 16.43% 16.46% 16.3% 16.17% 16.17% 15.93% 15.44%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Alembic Pharma Ltd (this stock) 20,652 23.0 3.48 13.4%
Shilpa Medicare Ltd 19,392 60.6 7.04 9.3%
Granules India Limited 22,226 31.7 3.39 13.8%
Onesource Specl Pharma L 18,464 1614.0 3.12 -1.09%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%

Which Mutual Funds Hold Alembic Pharma Ltd?

Frequently Asked Questions about Alembic Pharma Ltd

Community Sentiment

What are other investors saying about Alembic Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.